Holen Sie sich die Stockscreener-App
1.01
0.99%
-0.0101
Handel nachbörslich:
2.58
1.57
+155.45%
Schlusskurs vom Vortag:
$1.0201
Offen:
$1.0257
24-Stunden-Volumen:
5,146
Relative Volume:
0.41
Marktkapitalisierung:
$7.00M
Einnahmen:
-
Nettoeinkommen (Verlust:
$22.68M
KGV:
1.9057
EPS:
0.53
Netto-Cashflow:
$-1.94M
1W Leistung:
-0.98%
1M Leistung:
-3.81%
6M Leistung:
-41.28%
1J Leistung:
-54.50%
1-Tages-Spanne:
$1.00
$1.0299
1-Wochen-Bereich:
$1.00
$1.1257
52-Wochen-Spanne:
$1.00
$2.4229
Pharmacyte Biotech Inc Stock (PMCB) Company Profile
Firmenname
Pharmacyte Biotech Inc
Sektor
Branche
Telefon
(917) 595.2850
Adresse
23046 AVENIDA DE LA CARLOTA, SUITE 600, LAGUNA HILLS
Vergleichen Sie PMCB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| 2.24 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
0.4106 | 544.87M | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.67 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.145 | 315.50M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
SHMD
Schmid Group N V
|
2.67 | 120.14M | 0 | 0 | 0 | 0.00 |
|
DAVEW
Dave Inc
|
0.998 | 0 | 0 | 0 | 0 | 0.00 |
Pharmacyte Biotech Inc Aktie (PMCB) Neueste Nachrichten
Short Interest in PharmaCyte Biotech, Inc. (NASDAQ:PMCB) Increases By 382.4% - Defense World
PharmaCyte Biotech (OTCMKTS:PMCBD) Trading Up 3.8% – Here’s What Happened - Defense World
Malignant Ascites Pipeline 2025: Groundbreaking Clinical - openPR.com
PharmaCyte Biotech (OTCMKTS:PMCBD) Stock Price Up 1.9% – What’s Next? - Defense World
PharmaCyte Biotech (NASDAQ:PMCB) & LadRx (OTCMKTS:CYTR) Head to Head Analysis - Defense World
Malignant Ascites Treatment Market Detailed In New Research - openPR.com
PharmaCyte Biotech (OTCMKTS:PMCBD) Trading Up 1.7% – Still a Buy? - Defense World
PharmaCyte Biotech holds annual meeting, elects directors By Investing.com - Investing.com South Africa
PharmaCyte Biotech holds annual meeting, elects directors - Investing.com
PMCB stock touches 52-week low at $1.03 amid market challenges By Investing.com - Investing.com South Africa
PMCB stock touches 52-week low at $1.03 amid market challenges - Investing.com Australia
PharmaCyte Biotech (OTCMKTS:PMCBD) Stock Price Down 5.3% – Here’s What Happened - Defense World
Short Interest in PharmaCyte Biotech, Inc. (NASDAQ:PMCB) Grows By 82.3% - Defense World
PMCB stock touches 52-week low at $1.38 amid market challenges - Investing.com India
PharmaCyte Biotech Inc. (PMCB) reports earnings - Quartz
PharmaCyte Biotech, Inc. SEC 10-Q Report - TradingView
PharmaCyte Biotech (OTCMKTS:PMCBD) Shares Down 1.1% – Here’s What Happened - Defense World
Contrasting PharmaCyte Biotech (OTCMKTS:PMCBD) & Tarsus Pharmaceuticals (NASDAQ:TARS) - Defense World
Advantage Continues Refreshment of its Board of Directors - BOE Report
PharmaCyte Biotech appoints new accounting firm By Investing.com - Investing.com South Africa
PharmaCyte Biotech appoints new accounting firm - Investing.com
Top Penny Stocks To Watch In February 2025 - Simply Wall St
PharmaCyte Biotech (OTCMKTS:PMCBD) and Tenaya Therapeutics (NASDAQ:TNYA) Head to Head Analysis - The AM Reporter
Head to Head Survey: Tenaya Therapeutics (NASDAQ:TNYA) and PharmaCyte Biotech (OTCMKTS:PMCBD) - Defense World
Pancreatic Cancer Precision Medicine Market Report, 2030 - Grand View Research
Malignant Ascites Treatment Market: Trends, Growth, - openPR
Pancreatic Cancer Treatment Market to Surge to USD 10.2 - GlobeNewswire
PharmaCyte Biotech (OTCMKTS:PMCBD) Stock Price Up 0.1% – What’s Next? - Defense World
Global Ascites Market Size and Trends, Forecast 2025-2035: Unlocking Key Insights for Strategic Growth – Custom Market Insights - BioSpace
PharmaCyte Biotech, Inc. (NASDAQ:PMCB) Shares Sold by Geode Capital Management LLC - Defense World
PharmaCyte Biotech (OTCMKTS:PMCBD) Trading 1.5% Higher – Time to Buy? - Defense World
PharmaCyte Biotech (OTCMKTS:PMCBD) Stock Price Up 1.5% – Still a Buy? - Defense World
Comparing Vaxcyte (NASDAQ:PCVX) & PharmaCyte Biotech (OTCMKTS:PMCBD) - Defense World
Financial Comparison: Coeptis Therapeutics (NASDAQ:COEP) & PharmaCyte Biotech (NASDAQ:PMCB) - Defense World
PharmaCyte Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2024 - Marketscreener.com
CXApp (NASDAQ:CXAI) & Aware (NASDAQ:AWRE) Financial Contrast - Defense World
Zacks Research Issues Positive Estimate for SRPT Earnings - Defense World
PharmaCyte Biotech (OTCMKTS:PMCBD) Shares Down 2.4% – What’s Next? - Defense World
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Five Below, Inc. (FIVE) Investors - Business Wire
Pancreatic Cancer Treatment Market Size Worth USD 10.53 - GlobeNewswire
Banc of California, Inc. Announces Quarterly Dividends - Business Wire
MyMD Pharmaceuticals Receives FDA IND Clearance to Begin Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan - Marketscreener.com
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Conn's, Inc. (CONN) on Behalf of Investors - Business Wire
PROTEINA Co., Ltd. Announces Breakthrough Research Published in Nature Biomedical Engineering - Business Wire
MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc. - StockTitan
Avant Technologies Announces Leadership Shake-Up and New CEO - TipRanks
Thumbtack Partners with Red Ventures’ MyMove to Streamline Completing Home Projects - Business Wire
TDC Stockholders with Large Losses are Urged to Contact Robbins LLP for Information About the Teradata Corporation Class Action Lawsuit - Business Wire
Booz Allen Hamilton to Host Conference Call to Discuss First Quarter Fiscal 2025 Results on Friday, July 26, 2024 - Business Wire
ioXt Announces Major Strategic Shift Toward Secure IoT Platform-as-a-Service (PaaS) - Business Wire
Finanzdaten der Pharmacyte Biotech Inc-Aktie (PMCB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.91%
1.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):